It has been shown to inhibit the TLR4/NF‐κB/NLRP3 pathway, a key receptor in the Toll‐like receptor family that mediates LPS‐stimulated tissue damage, apoptosis, and inflammation, thus protecting VECs and preventing thrombosis and atherosclerosis progression (Liu et al. 2024). This evidence concerns the gene NFKB1 and atherosclerosis.